Methods of treating acute myeloid leukemia with a flt3 mutation
AssigneesBiokine Therapeutics Ltd., BioLineRx Ltd.
InventorsAmnon PELED, Michal ABRAHAM
Life of this patent
Estimating the term…
Abstract
There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.
Claims22
A method of treating acute myeloid leukemia (AML), the method comprising administrating to a subject having AML with a FMS-like tyrosine kinase 3 (FLT3) mutation a therapeutically effective amount of a CXCR4-antagonistic peptide, thereby treating the AML.
A method of treating acute myeloid leukemia (AML), the method comprising the steps of:
- (a) identifying a subject having AML with a FMS-like tyrosine kinase 3 (FLT3) mutation;
- and
- (b) administrating to said subject a therapeutically effective amount of a CXCR4-antagonistic peptide, thereby treating the AML with a FLT3 mutation.
3-4. (canceled)
An article of manufacture identified for the treatment of AML with a FMS-like tyrosine kinase 3 (FLT3) mutation comprising a CXCR4-antagonistic peptide and a chemotherapeutic agent.
Dependencies are inferred from the claim text.